Sheaff Brock Investment Advisors LLC grew its position in Amgen, Inc. (NASDAQ:AMGN) by 18.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,099 shares of the medical research company’s stock after purchasing an additional 6,753 shares during the period. Amgen makes up approximately 1.0% of Sheaff Brock Investment Advisors LLC’s holdings, making the stock its 23rd largest holding. Sheaff Brock Investment Advisors LLC’s holdings in Amgen were worth $7,495,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Baker Ellis Asset Management LLC acquired a new position in Amgen during the 3rd quarter worth approximately $108,000. Phocas Financial Corp. acquired a new position in Amgen during the 2nd quarter worth approximately $110,000. Barrow Hanley Mewhinney & Strauss LLC lifted its position in Amgen by 110.7% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock worth $113,000 after acquiring an additional 340 shares in the last quarter. Taylor Hoffman Wealth Management acquired a new position in Amgen during the 4th quarter worth approximately $127,000. Finally, Salem Investment Counselors Inc. lifted its position in Amgen by 4.7% during the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after acquiring an additional 36 shares in the last quarter. 79.55% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 4,575 shares of company stock valued at $838,064 over the last quarter. Company insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same period in the previous year, the company earned $2.89 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. sell-side analysts expect that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.
Amgen announced that its Board of Directors has authorized a share buyback plan on Thursday, February 1st that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.14%. Amgen’s dividend payout ratio (DPR) is 41.97%.
Several research firms recently commented on AMGN. Argus raised Amgen from a “hold” rating to a “buy” rating and boosted their price target for the stock from $192.33 to $220.00 in a research report on Tuesday, January 23rd. JPMorgan Chase boosted their price target on Amgen from $184.00 to $189.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 24th. Royal Bank of Canada reissued a “hold” rating and set a $189.00 price target on shares of Amgen in a research report on Wednesday, January 24th. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $181.60 price target on the stock. in a research report on Tuesday, March 6th. Finally, BMO Capital Markets boosted their price target on Amgen from $192.00 to $202.00 and gave the stock a “market perform” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company’s stock. Amgen has an average rating of “Hold” and a consensus target price of $190.57.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3343102/amgen-inc-amgn-shares-bought-by-sheaff-brock-investment-advisors-llc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.